Abstract
AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.
| Original language | English (US) |
|---|---|
| Journal | Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery |
| Volume | 33 |
| Issue number | 1 Suppl |
| DOIs | |
| State | Published - Mar 2013 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
A review of AbobotulinumtoxinA (Dysport). / Lorenc, Z. Paul; Kenkel, Jeffrey M.; Fagien, Steven; Hirmand, Haideh; Nestor, Mark S.; Sclafani, Anthony P.; Sykes, Jonathan M; Waldorf, Heidi A.
In: Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, Vol. 33, No. 1 Suppl, 03.2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A review of AbobotulinumtoxinA (Dysport).
AU - Lorenc, Z. Paul
AU - Kenkel, Jeffrey M.
AU - Fagien, Steven
AU - Hirmand, Haideh
AU - Nestor, Mark S.
AU - Sclafani, Anthony P.
AU - Sykes, Jonathan M
AU - Waldorf, Heidi A.
PY - 2013/3
Y1 - 2013/3
N2 - AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.
AB - AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.
UR - http://www.scopus.com/inward/record.url?scp=84883047499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883047499&partnerID=8YFLogxK
U2 - 10.1177/1090820X12474632
DO - 10.1177/1090820X12474632
M3 - Article
C2 - 23515194
AN - SCOPUS:84883047499
VL - 33
JO - Aesthetic Surgery Journal
JF - Aesthetic Surgery Journal
SN - 1090-820X
IS - 1 Suppl
ER -